Telix Pharmaceuticals Limited (ASX: TLX)

Telix Pharmaceuticals Ratios and Metrics

Market cap in millions AUD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 19, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	8,280	3,263	2,300	2,209	1,060	393
Market Cap Growth	74.40%	41.89%	4.10%	108.44%	169.99%	176.59%
Enterprise Value	8,183	3,145	2,180	2,161	1,039	384
Last Close Price	24.74	10.08	7.27	7.75	3.78	1.55
PE Ratio	168.20	626.21	-	-	-	-
Forward PE	97.36	32.83	-	-	-	-
PS Ratio	12.43	6.49	14.37	290.85	203.32	112.65
PB Ratio	20.47	21.91	28.75	1023.78	13.41	5.60
P/TBV Ratio	1387.98	83.14	109.40	-	53.46	13.95
P/FCF Ratio	215.92	229.72	-	-	619.12	-
P/OCF Ratio	125.41	136.63	-	-	540.78	-
EV/Sales Ratio	12.67	6.26	13.62	284.54	199.24	110.26
EV/EBITDA Ratio	109.70	55.00	-	-	-	-
EV/EBIT Ratio	121.50	60.60	-	-	-	-
EV/FCF Ratio	213.40	221.37	-	-	606.68	-
Debt / Equity Ratio	0.05	0.12	0.13	1.18	0.03	0.03
Debt / EBITDA Ratio	0.30	0.30	-	-	-	-
Debt / FCF Ratio	0.58	1.23	-	-	1.29	-
Asset Turnover	1.22	1.54	0.88	0.06	0.04	0.04
Inventory Turnover	11.07	14.59	10.92	1.25	3.45	4.29
Quick Ratio	0.81	1.24	1.90	1.13	4.62	5.42
Current Ratio	0.99	1.43	2.02	1.25	4.69	5.52
Return on Equity (ROE)	20.49%	4.55%	-253.34%	-198.36%	-60.21%	-45.32%
Return on Assets (ROA)	7.97%	9.92%	-25.37%	-37.95%	-23.64%	-28.06%
Return on Capital (ROIC)	16.34%	25.26%	-97.35%	-118.20%	-40.13%	-39.67%
Earnings Yield	0.59%	0.16%	-4.53%	-3.64%	-4.23%	-7.10%
FCF Yield	0.46%	0.44%	-3.09%	-2.75%	0.16%	-6.05%
Buyback Yield / Dilution	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%
Total Shareholder Return	-5.90%	-4.21%	-10.08%	-9.69%	-10.21%	-15.49%

Source: S&P Capital IQ. Standard template. Financial Sources.